MINNEAPOLIS, Feb. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2024. The quarterly dividend will be payable February 28, 2025, to all common shareholders of record on February 17, 2025. Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools ...

MINNEAPOLIS, Feb. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ending December 31, 2024.Second Quarter FY2025 Highlights Second quarter organic revenue increased by 9% (9% reported) to $297.0 million. GAAP earnings per share (EPS) was $0.22 versus $0.17 one year ago. Delivered adjusted EPS of $0.42 compared to $0.40 one year ago. Improving biopharma end-market conditions combined with continued momentum of our cell and gene therapy ...

MINNEAPOLIS, Feb. 4, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the appointment of Amy E. Herr, Ph.D. to serve as an independent director on the Company's Board of Directors beginning on February 1, 2025. Dr. Herr will serve on the Science & Technology Committee of the Board of Directors.Dr. Herr is a Chancellor's Professor of Bioengineering at the University of California, Berkeley. Dr. Herr also currently serves as the Vice President of the Chan Zuckerberg Biohub Network, a ...

Bio-Techne Corporation (TECH) is set to release its second-quarter fiscal 2025 results on Feb. 5, before the opening bell.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The life science and diagnostic product maker posted adjusted earnings per share (EPS) of 42 cents in the last reported quarter, which exceeded the Zacks Consensus Estimate by 10.53%. The company topped earnings estimates in two of the trailing four quarters and missed in the other two, the average surprise being 1.55 ...

Company Overview - CMBTECH is a diversified maritime group owning and operating over 160 seagoing vessels including crude oil tankers dry bulk vessels container ships chemical tankers offshore wind vessels tugboats and ferries [2] - The company also provides hydrogen and ammonia fuel to customers through its own production or third-party producers [2] - Headquartered in Antwerp Belgium with offices across Europe Asia the United States and Africa [3] - Listed on Euronext Brussels and the NYSE under the ticker symbol CMBT [3] Recent Transactions - CMBTECH sold several vessels generating a total capital gain of 4652 million USD [1] - Suezmax Cap Lara (2007 158826 dwt) sold for a capital gain of 1877 million USD with delivery scheduled for Q1 2025 [1] - VLCC Alsace (2012 299999 DWT) delivered to new owner with a capital gain of approximately 275 million USD to be booked in Q1 2025 [2] - Windcat 6 sold after 18 years of service generating a capital gain of 025 million USD with delivery expected by end of January 2025 [2] Upcoming Announcement - CMBTECH will announce its Q4 2024 results on 27 February 2025 [2]

ST. PAUL, Minn., Jan. 21, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that BrainChild Bio has been awarded a $300,000 G-Rex® Grant. The G-Rex® Grant will support expeditious process development and commercial readiness of BCB-276, BrainChild Bio's lead autologous CAR-T therapy for the treatment of diffuse intrinsic pontine glioma (DIPG), an incurable type of pediatric brain tumor. BrainChild Bio plans to advance BCB- ...

Bio-Techne Corporation (TECH) recently announced the launch of a new line of designer proteins engineered using advanced artificial intelligence (AI)- based design platforms and protein evolutionary workflows. The company’s new designer proteins are now available as part of its market-leading R&D Systems branded portfolio of proteins. With this expanded portfolio, Bio-Techne continues to lead the way in delivering innovations to the life sciences and therapeutic development communities. The latest launch is ...

Product Portfolio Expansion - The company has launched a new portfolio of designer proteins engineered using advanced AI-based design platforms and protein evolutionary workflows [4] - The expanded portfolio includes IL-2 Heat Stable Agonist, Activin A Hyperactive, FGF basic Heat Stable, and Wnt/RSPO1, Wnt/RSPO2, and Wnt/RSPO3 Agonist proteins [4] - These proteins are designed to address critical needs in cellular therapy workflows and research applications, including improved cell culture performance and optimized cell expansion [2] Technological Innovation - The company leverages generative AI trained on data developed over almost five decades of proteomic leadership, protein library evolution, and rational design [2] - The new proteins feature tailored functionalities such as hyperactivity, enhanced receptor affinities, and improved heat stability [2] - The FGF basic Heat Stable protein is available in both RUO and GMP formats to support cell therapy manufacturing and advanced research [3] Market Leadership - The company continues to lead in delivering disruptive innovations to the life sciences and therapeutic development communities [5] - The designer proteins are part of the company's market-leading R&D Systems branded portfolio of proteins [5] Company Overview - The company is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostic communities [6] - It generated approximately $1.2 billion in net sales in fiscal 2024 and has over 3,100 employees worldwide [6]

ST. PAUL, Minn., Jan. 8, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing and Bio-Techne Corporation, today announced that Seattle Children's Therapeutics, a division of the Seattle Children's Research Institute has been awarded a $125,000 G-Rex Grant.  The G-Rex Grant will integrate state-of-the-art advancements into Seattle Children's Therapeutics' G-Rex based CAR-T cell platform. "This technology has been a core component of our CAR-T platform for many years, and we have m ...

MINNEAPOLIS, Jan. 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it prevailed on another claim that Miltenyi Biotec B.V. & Co. KG commercialized antibodies developed based on information obtained by reverse engineering Bio-Techne's proprietary R&D Systems branded NKG2C/CD159c antibodies. This follows a similar case from 2023, where Miltenyi was found to have reversed engineered and commercialized Bio-Techne's proprietary R&D Systems branded TIGIT and CCR-7 antibodies.   B ...